Study #2025-0580
Phase 2 study assessing the clinical activity and safety of obecabtagene autoleucel as a consolidation in patients with newly diagnosed high-risk B-cell acute lymphocytic leukemia (ALL)
MD Anderson Study Status
Enrolling
Treatment Agent
Obecabtagene autoleucel
Description
The goal of this clinical research study is to learn if obecabtagene autoleucel (obe-cel) can help to control newly diagnosed, high-risk B-cell ALL when given as consolidation therapy. Consolidation therapy is given after the first phase of treatment.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Lymphocytic Leukemia (ALL)
Study phase:
Phase II
Physician name:
Elias Jabbour
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.